Dr Reddys Laboratories (RDY) EBITDA Margin (2009 - 2026)
Dr Reddys Laboratories' EBITDA Margin was 11.35% in the quarter ended Jun 30, 2026, down 14.68 percentage points from 26.03% a year earlier and down 702.95 percentage points from the prior quarter.
Dr Reddys Laboratories (RDY) EBITDA Margin (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Dr Reddys Laboratories' EBITDA Margin was 319.37% through Jun 30, 2026, up 297.75 percentage points year-over-year; for the year ended Mar 31, 2026, it was 21.20%, down 6.06 percentage points from the prior year.
- EBITDA Margin shows a five-year change of +1.66 percentage points (years ended Mar 2021 to Mar 2026).
- In earlier years, EBITDA Margin was 27.26% in the year ended Mar 31, 2025 (-2.32 pp), 29.58% in the year ended Mar 31, 2024 (+1.21 pp), 28.38% in the year ended Mar 31, 2023 (+9.09 pp) and 19.29% in the year ended Mar 31, 2022 (-0.26 pp).
- The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly EBITDA Margin since the quarter ended Mar 31, 2025.
- Compared with a year earlier, EBITDA Margin was higher in three of the last eight quarters, with an average year-over-year change of +154.85 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was the quarter ended Mar 31, 2026 (a gain of 708.69 percentage points); the worst was the quarter ended Mar 31, 2024 (a drop of 25.25 percentage points).
- Per Business Quant data, RDY's EBITDA Margin in the three quarters before the quarter ended Jun 30, 2026 was 714.30% (quarter ended Mar 31, 2026), 558.59% (quarter ended Dec 31, 2025) and 25.62% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Dr Reddys Laboratories | 10.44 Bn | 9.62 Bn | 396.53 Mn | 11.35% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.35% |
| Mar 31, 2026 | 714.30% |
| Dec 31, 2025 | 558.59% |
| Sep 30, 2025 | 25.62% |
| Jun 30, 2025 | 26.03% |
| Mar 31, 2025 | 5.61% |
| Dec 31, 2024 | 28.04% |
| Sep 30, 2024 | 26.84% |
| Jun 30, 2024 | 28.33% |
| Mar 31, 2024 | 5.68% |
| Dec 31, 2023 | 5.53% |
| Sep 30, 2023 | 31.48% |
| Jun 30, 2023 | 31.21% |
| Mar 31, 2023 | 30.92% |
| Dec 31, 2022 | 24.88% |
| Sep 30, 2022 | 29.03% |
| Jun 30, 2022 | 29.26% |
| Mar 31, 2022 | 8.23% |
| Dec 31, 2021 | 16.00% |
| Sep 30, 2021 | 23.15% |
Dr Reddys Laboratories EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();